

**Form 51-102F3
Material Change Report**

1. Name and Address of Company

Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB T3E 6L1

2. Date of Material Change

September 30, 2019

3. News Release

September 30, 2019 via GlobeNewswire

4. Summary of Material Change

Resverlogix Corp. announced that its Phase 3 BETonMACE clinical trial did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke – added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol.

5. Full Description of Material Change

Resverlogix Corp. announced that the Phase 3 BETonMACE clinical trial of its lead drug, apabetalone, did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke – added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol. Apabetalone demonstrated tolerability and safety. The primary results of the BETonMACE trial will be presented in the near future during the American Heart Association's Scientific Sessions 2019 held in Philadelphia, Pennsylvania, and submitted for peer review.

6. Reliance of subsection 7.1(2) of National Instrument 51-102

Not applicable

7. Omitted Information

Not applicable

8. Executive Officer

Donald J. McCaffrey, President and CEO
Telephone: (403) 254-9252

9. Date of Report

October 8, 2019